KeyCorp vs Twist Bioscience Corp — how do they compare? KeyCorp trades at $19.98 (market cap $21.45B), while Twist Bioscience Corp trades at $159.64 (market cap $10.08B). The key difference: KeyCorp is far larger — about 2.1× Twist Bioscience Corp's market cap, and KeyCorp pays a 4.08% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Twist Bioscience Corp for 27 Days on average.
| KEY | TWST | |
|---|---|---|
Market Cap | $21.45B | $10.08B |
Volume | 19,450,846 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $23.99 | $205.00 |
52-Week Low | $16.78 | $25.45 |
Typical Hold Time | 66 Days | 27 Days |
Enterprise Value | $34.63B | $10.01B |
Dividend Yield | 4.08% | — |
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.985, up 0.78% on the day, with strong fundamental metrics including a P/E of 11.75 and net income margin of 26.72%. The stock shows consistent earnings beats in recent quarters and maintains a solid dividend yield. Technical indicators suggest bearish momentum despite neutral oscillators, while analyst consensus remains strongly bullish with a $25.00 price target representing 25% upside potential from current levels.
KEY presents a compelling value opportunity with attractive valuation multiples and strong profitability, though technical weakness and frozen dividend payments pose near-term concerns. The bank's improved revenue guidance for 2026 and aggressive share buyback program support EPS growth, while interest rate sensitivity remains a key risk factor for the regional banking sector.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →